Luchin F. Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luchin F. Wong has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Robert M. Silver
Department of Obstetrics and Gynecology, University of Utah School of Medicine, and Department of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, UT
2 shared publicationsAijun Ye
Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD
1 shared publicationAnne M. Lynch
Department of Obstetrics and Gynecology, School of Medicine, University of Colorado, Denver, CO
1 shared publicationCalla M. Holmgren
Department of Obstetrics and Gynecology, University of Utah School of Medicine, and Department of Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, UT
1 shared publicationDavid Faraggi
Department of Statistics, University of Haifa, Haifa, Israel
1 shared publication- Enrique F. Schisterman
Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
1 shared publication
Latest Publications
- 1 March 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (3) , 375.e1-375.e11
The effect of a very short interpregnancy interval and pregnancy outcomes following a previous pregnancy loss
- 1 March 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (3) , 375.e1-375.e11
The effect of a very short interpregnancy interval and pregnancy outcomes following a previous pregnancy loss
- 1 February 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (2) , 215.e1-215.e9
Outcomes of expectantly managed pregnancies with multiple gestations and preterm premature rupture of membranes prior to 26 weeks
- 1 February 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (2) , 215.e1-215.e9
Outcomes of expectantly managed pregnancies with multiple gestations and preterm premature rupture of membranes prior to 26 weeks
- 16 September 2014
- Published by SAGE Publications in Lupus
- Vol. 23 (12) , 1226-1228
Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand?
Evidence from basic science studies supports a causative relationship between antiphospholipid antibodies (aPL) and recurrent early miscarriage (REM) (prior to 10 weeks of gestation). However, human studies have not consistently found a relationship between aPL and REM. Members of the Obstetric Task Force of the 14th International Congress on Antiphospholipid Antibodies performed a literature review of the association of aPL and REM and searched for clinical trials in women with REM who tested positive for aPL. Of the 46 studies that investigated the relationship between aPL and REM, 27 found a positive association, seven found no association, and the remaining 12 papers could not report an association (lack of control group). The main identified problems for such conflicting results were varying definitions of REM (two or three abortions, not necessarily consecutive; different gestational age at which pregnancy losses occurred); analysis of patients with previous fetal death (>10 weeks) in the same group of REM; and different definitions of “positive aPL” (cutoffs not following international recommendations; small number of studies confirmed persistence of positive aPL after six to 12 weeks). The 10 identified randomized trials with proposed treatments for women with REM who test positive for aPL also had heterogeneous inclusion criteria, with only one trial limited to subjects who would meet the current criteria for antiphospholipid syndrome (APS) by both clinical and laboratory criteria. Against this background, we conclude that the association between REM and aPL remains inconclusive and that the findings of treatment trials are at best inconsistent and at worst misleading. More convincing data are critically needed. Studies that identify, or at least stratify, according to international consensus criteria and include standardized core laboratory testing results are crucial if we are to establish an evidence-based association between aPL and REM and treatment recommendations.
- 16 September 2014
- Published by SAGE Publications in Lupus
- Vol. 23 (12) , 1226-1228
Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand?
Evidence from basic science studies supports a causative relationship between antiphospholipid antibodies (aPL) and recurrent early miscarriage (REM) (prior to 10 weeks of gestation). However, human studies have not consistently found a relationship between aPL and REM. Members of the Obstetric Task Force of the 14th International Congress on Antiphospholipid Antibodies performed a literature review of the association of aPL and REM and searched for clinical trials in women with REM who tested positive for aPL. Of the 46 studies that investigated the relationship between aPL and REM, 27 found a positive association, seven found no association, and the remaining 12 papers could not report an association (lack of control group). The main identified problems for such conflicting results were varying definitions of REM (two or three abortions, not necessarily consecutive; different gestational age at which pregnancy losses occurred); analysis of patients with previous fetal death (>10 weeks) in the same group of REM; and different definitions of “positive aPL” (cutoffs not following international recommendations; small number of studies confirmed persistence of positive aPL after six to 12 weeks). The 10 identified randomized trials with proposed treatments for women with REM who test positive for aPL also had heterogeneous inclusion criteria, with only one trial limited to subjects who would meet the current criteria for antiphospholipid syndrome (APS) by both clinical and laboratory criteria. Against this background, we conclude that the association between REM and aPL remains inconclusive and that the findings of treatment trials are at best inconsistent and at worst misleading. More convincing data are critically needed. Studies that identify, or at least stratify, according to international consensus criteria and include standardized core laboratory testing results are crucial if we are to establish an evidence-based association between aPL and REM and treatment recommendations.